Share
     
Title
Code
Session Type
Venue
Date Time
Co-Chairs:
14:30
TUAA0101
Two-year post-vaccination follow-up from APPROACH: Phase 1/2a randomized study evaluating safety and immunogenicity of prophylactic HIV vaccine regimens combining Ad26.Mos.HIV and gp140 envelope protein
Frank Tomaka, Janssen Research and Development, United States
Abstract
14:45
TUAA0102
Protein-supplemented DNA/MVA vaccines: Preclinical immunogenicity and protection for transmitted/founder (B.63521Δ11mutC) and CD4-induced gp120 (rhFLSC) proteins
Harriet L. Robinson, GeoVax Inc., United States
Abstract
15:00
TUAA0103
A vaccine targeting HIV maturation protects Cynomolgus monkeys against vaginal SIVmac251 acquisition
Ma Luo, National Microbiology Lab, Public Health Agency of Canada and University of Manitoba, Canada
Abstract
15:15
TUAA0104
A helical structure in the V2 domain of gp120 that localizes to the site of immune pressure in the RV144 vaccine trial is conserved in HIV and SIV envelopes
James Arthos, National Institute of Allergy and Infectious Diseases, United States
Abstract
Slides
15:30
TUAA0105
Lessons from the Research in Viral Eradication of Reservoirs (RIVER) study: Impact of a therapeutic vaccine targeting conserved HIV epitopes on T cell function in treated primary infection
Jakub Kopycinski, Oxford University, United Kingdom
Abstract
Slides
AUTHOR
SUMMARY
HIGHLIGHTS
CRITICAL ASSESSMENT